OS Therapies Inc. (NYSE American: OSTX) announced its participation in the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference, scheduled for September 9-10 in New York City. The company will engage with investors and strategic partners at the event, with its OS Animal Health division also in attendance. This appearance comes at a potentially pivotal time for the company's lead investigational therapy, OST-HER2, as it approaches a series of regulatory milestones.
The company is entering a significant regulatory period for OST-HER2, an immunotherapy designed for patients with fully resected pulmonary metastatic osteosarcoma, a rare bone cancer. In September, OS Therapies expects to receive interim three-year overall survival data from its clinical trials. Additionally, the company has key meetings scheduled with the U.S. Food and Drug Administration (FDA) and U.K. regulatory authorities. These discussions could lead to decisions on Regenerative Medicine Advanced Therapy (RMAT) designation and Rolling Review, which are designed to expedite the development and review of promising therapies.
The company anticipates final three-year data in the fourth quarter of 2026, followed by a U.S. Pre-BLA (Biologics License Application) meeting and regulatory submissions in the U.S., U.K., and Europe. Success in these milestones could bring OST-HER2 closer to market approval, offering a potential new treatment option for osteosarcoma patients who currently have limited choices after surgery.
OST-HER2 leverages a novel mechanism of action. It is a gene-edited, listeria-based cancer immunotherapy that stimulates the immune system to target the HER2 protein, which is overexpressed in certain tumors. The therapy is designed to recognize three distinct epitopes of the HER2 oncogene, requiring only one to be present to trigger an immune response. This approach aims to attack both primary tumors and micro-metastases, potentially reducing the risk of recurrence.
The therapy has already received multiple regulatory designations aimed at accelerating its development. In the U.S., OST-HER2 has been granted Orphan Drug Designation (ODD), Fast Track Designation (FTD), and Rare Pediatric Disease Designation (RPDD) from the FDA. In Europe, it has received ODD, FTD, and Advanced Therapy Medicinal Products (ATMP) classification from the European Medicines Agency.
In addition to its human oncology focus, OS Therapies is also advancing OST-HER2 in veterinary medicine. OS Animal Health is seeking alignment with the U.S. Department of Agriculture (USDA) to reinstate conditional approval for OST-HER2 in canine osteosarcoma, a common cancer in dogs. This dual-track approach could expand the company's market opportunities and provide benefits for both human and animal patients.
The upcoming conference and regulatory milestones are critical for OS Therapies as it seeks to bring OST-HER2 to market. Osteosarcoma is the most common type of bone cancer, primarily affecting children and young adults. Current treatments include surgery and chemotherapy, but outcomes remain poor for patients with metastatic disease. An effective immunotherapy could significantly improve survival rates.
Investors and industry observers will be watching closely as OS Therapies navigates these regulatory interactions. The company's progress could have substantial implications for the oncology landscape, particularly in the field of rare cancers. With a potential approval in sight, OST-HER2 may represent a new paradigm in cancer treatment, harnessing the body's immune system to fight malignancies.
For more information about OS Therapies, visit www.ostherapies.com. To view the full press release, visit https://ibn.fm/ERaOp.
